Skip to main content
Scope Fluidics S.A. logo

Scope Fluidics S.A. — Investor Relations & Filings

Ticker · SCP ISIN · PLSCPFL00018 LEI · 259400EUNFX4E2BEHU15 WAR Professional, scientific and technical activities
Open in API
Filings indexed 518 across all filing types
Latest filing 2023-06-12 Management Reports
Country PL Poland
Listing WAR SCP

About Scope Fluidics S.A.

https://scopefluidics.com/

Scope Fluidics S.A. is a biotechnology company that develops innovative medical diagnostic solutions based on microfluidic technologies. The company's business model involves incubating projects within special-purpose vehicles (SPVs) with the goal of selling them to global strategic partners. Its primary project, developed by its subsidiary Bacteromic Sp. z o.o., is the BACTEROMIC system. This automated system provides rapid, comprehensive antimicrobial susceptibility testing (AST) to address the challenge of antibiotic resistance. Previously, the company developed the PCR|ONE system for rapid molecular diagnostics through its Curiosity Diagnostics SPV, which was acquired by Bio-Rad in 2022. The company focuses on creating fast, effective, and accessible diagnostic tools to improve healthcare outcomes.

Recent filings

Filing Released Lang Actions
Podsumowanie dotychczasowych działąń w ramach Scope Discovery
Management Reports Classification · 95% confidence The document is written in Polish and details the initial activities, team building, methodology, and project qualification process for a new internal structure called 'Scope Discovery' within the company Scope Fluidics. It discusses strategy, project portfolio balancing (CORE, ADJACENT, EXPLORATION), sources of ideas, and the two-stage evaluation process (Concept and Proof-of-Concept). This content strongly suggests a strategic update or a management discussion about internal operations and future development pipeline, rather than a formal financial filing like a 10-K, an Earnings Release (ER), or a Dividend Notice (DIV). It aligns best with Management Reports (MDA), which typically contain management's detailed explanation of business trends and outlook, even if focused on R&D or strategic initiatives rather than just financial results. It is not a standard regulatory filing (like 10-K or IR) nor a short announcement (like RPA/RNS). It is a detailed narrative update on strategic execution.
2023-06-12 Polish
Podsumowanie działań w ramach Scope Discovery - Content (PL)
Board/Management Information Classification · 99% confidence The document is a formal announcement from Scope Fluidics S.A. regarding an update on its 'Scope Discovery' structure, which relates to its development strategy. It references a previous current report (raport bieżący nr 9/2023) and explicitly states that the description of the activities is provided as an attachment ('Opis powyższych działań stanowi załącznik do niniejszego raportu.'). Since the document itself is short (1994 characters) and serves primarily to announce the availability of detailed information (the attachment/description), it fits the definition of a Report Publication Announcement (RPA) rather than the detailed report itself (like IR or MDA). The content discusses strategy and internal development processes, which aligns with strategic updates often announced via RPA or RNS, but the explicit mention of an attachment points strongly to RPA.
2023-06-12 Polish
Dopuszczenie i wprowadzenie akcji Emitenta do obrotu giełdowego na rynku regulowanym prowadzonym przez GPW - Content (PL)
Share Issue/Capital Change Classification · 99% confidence The document is a short announcement (997 characters) from the Management Board of Scope Fluidics S.A. regarding the admission and introduction of 39,725 new ordinary shares (Series J) to trading on the Warsaw Stock Exchange (GPW). This concerns a change in the company's capital structure due to the exercise of subscription warrants. Since it announces a specific corporate action related to share issuance/capital change, the most appropriate category is Share Issue/Capital Change (SHA). It is not a general regulatory filing (RNS) because it fits a more specific category, and it is not an RPA because it describes the event itself rather than just announcing the publication of a report.
2023-06-02 Polish
Rozszerzony skonsolidowany raport Scope Fluidics za I kwartał 2023 r.
Interim / Quarterly Report Classification · 100% confidence The document is a 'Skonsolidowany raport kwartalny' (Consolidated Quarterly Report) for Scope Fluidics S.A. for the three-month period ending March 31, 2023. It contains detailed financial statements (balance sheet, income statement, cash flow) and management commentary. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q1 2023
2023-05-30 Polish
Cele operacyjne w ramach projektu BacterOMIC
Regulatory Filings Classification · 95% confidence The document details operational goals (Cel I, Cel II, Cel III) related to the BacterOMIC system, including starting Early Access Program tests, commencing commercial production, and expanding the product/patent portfolio. It outlines timelines (end of 2023, first half of 2024) and discusses regulatory steps like CE-IVD certification, IVDR compliance, and FDA preparation. This content strongly suggests a strategic update or a detailed report on operational progress and future plans, rather than a formal regulatory filing like a 10-K, an earnings release (ER), or a simple dividend announcement. Since it focuses heavily on strategy, product development, and future milestones, it aligns best with an Investor Presentation (IP) or a Management Discussion & Analysis (MDA). Given the detailed breakdown of operational steps, timelines, and regulatory pathways, it functions as a comprehensive update for investors, making 'Investor Presentation' (IP) the most fitting category, although it shares characteristics with MDA. Since it is a detailed plan/update rather than a summary of past financial results, IP is preferred over MDA.
2023-05-29 Polish
Cele operacyjne w ramach projektu BacterOMIC - Content (PL)
Management Reports Classification · 92% confidence The document is a formal announcement in Polish ('raport bieżący' suggests a current report) referencing a previous report and detailing specific short-term objectives ('Cele') approved by the Supervisory Board regarding the BacterOMIC project. It discusses strategic development, commercialization goals (Early Access Program, commercial production, patent portfolio expansion), and potential strategic transactions. This content relates to the company's strategic direction, business plans, and operational milestones, which aligns best with a general strategic update or management disclosure rather than a specific financial report (like 10-K or IR) or a simple announcement of a report (RPA). Given the focus on strategy and management decisions regarding future business direction, it fits closest to a general strategic/management disclosure. Since there isn't a perfect 'Strategy Update' code, and it details management/board-approved objectives, it is classified as Management Reports (MDA) or potentially Regulatory Filings (RNS) if it's a standard regulatory disclosure not covered elsewhere. Given the detailed nature of the strategic goals, MDA is a strong fit, although RNS is often used for Polish 'raporty bieżące' that aren't standard SEC forms. However, the content is about management's plans and objectives, making MDA the most descriptive category among the options provided, as it covers business trends and outlook.
2023-05-29 Polish

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.